To the Editor We read with interest the article published by He et al1 focusing on sorafenib with hepatic arterial infusion of chemotherapy (HAIC). He et al1 conducted an open-label phase 3 randomized clinical trial with HAIC using leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) in addition to sorafenib vs sorafenib alone in patients with hepatocellular carcinoma (HCC) and a portal vein tumor thrombosis. The study met its primary end point, median overall survival, and identified an interesting overall response rate (ORR) in this situation (40.8%).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Palmieri L, Dermine S, Coriat R. Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma. JAMA Oncol. 2019;5(12):1805–1806. doi:10.1001/jamaoncol.2019.4052
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.